Unoje, O, Hussain, Y, Habib, A, Claeys, K, Gwathmey, K, Sahagian, G, Cortés-Vicente, E, Liu, L, Jimenez, R, Patel, M, Masschaele, D, Mantegazza, R, Meisel, A, Seth, A, Attarian, S. Sustained Clinical Efficacy and Long-Term Safety of Intravenous Efgartigimod for Generalized Myasthenia Gravis: Part B of ADAPT NXT. ANNALS OF NEUROLOGY. 2025; 98DOI:. PMID:. IF:7.700(Q1/1D).

Sánchez-Aced, E, Moya-Llamas, B, Escabias, JA, Torres, S, Colom-Cadena, M, Pegueroles, J, de Quintana-Schmidt, C, Bayes, A, Molina-Porcel, L, Aldecoa, I, Belbin, O, Fortea, J, Spires-Jones, T, Pujals, S, Sirisi, S, Lleo, A. Enhancing Lateral Resolution Using Two-Colour Direct Stochastic Optical Reconstruction Microscopy to Unravel Synaptic Tau Pathology in Alzheimer's Disease. NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY. 2025; 51(2)DOI:10.1111/nan.70010. PMID:40025904. IF:3.400(Q1/3D).

Martín-Aguilar, L, Querol, L. Reply to "Letter to the Editor: Pitfalls in Calculating the Incidence of GBS During the Pandemic". EUROPEAN JOURNAL OF NEUROLOGY. 2025; 32(2)DOI:10.1111/ene.70069. PMID:39931912. IF:3.900(Q1/3D).

Neal, MA, Bolano-Diaz, CF, Richardson, M, Michell-Sodhi, J, Muni-Lofra, R, James, MK, Hollingsworth, KG, Hilsden, H, Wilson, I, Blamire, AM, Straub, V, Thelwall, PE, Diaz-Manera, J. Rapid Quantitative Assessment of Muscle Sodium Dynamics After Exercise Using 23Na-MRI in Dysferlinopathy and Healthy Controls. Journal of Cachexia Sarcopenia and Muscle. 2025; 16(1)DOI:10.1002/jcsm.13709. PMID:39900102. IF:9.100(Q1/1D).

Dominguez-González, C, Iannucci, D, Clark, J, Martin-Jiménez, P, Hold, S, Oliva, P, Bischinger, A, Gallardo, E, Diaz-Manera, J. Urinary glucose tetrasaccharide tracks disease activity in late-onset Pompe disease. NEUROMUSCULAR DISORDERS. 2026; 60DOI:10.1016/j.nmd.2026.106359. PMID:41638029. IF:2.800(Q2/5D).

Vesperinas, A, Rocaspana-Codana, J, Reyes-Leiva, D, Caballero-Avila, M, Carbayo, A, Collet-Vidiella, R, Llanso, L, Gallardo, E, Turon-Sans, J, Rojas-Garcia, R, Cortes-Vicente, E. Challenges in myasthenia gravis diagnosis: an analysis of the diagnostic process of myasthenia gravis in a specialized clinic. NEUROMUSCULAR DISORDERS. 2026; 59DOI:10.1016/j.nmd.2025.106284. PMID:41442860. IF:2.800(Q2/5D).

Schirinzi, E, Bochicchio, MA, Lochmüller, H, Vissing, J, Jordie-Diaz-Manerae, Evangelista, T, Plançon, JP, Fanucci, L, Marini, M, Tonacci, A, Mancuso, M, Segovia-Kueny, S, Toscano, A, Angelini, C, Schoser, B, Sacconi, S, Siciliano, G, e-NMD Grp. E-Health & Innovation to Overcome Barriers in Neuromuscular Diseases. Report from the 3rd eNMD Congress: Pisa, Italy, 29-30 October 2021: Remote Monitoring: New Solutions for New Avenues in Neuromuscular Disorders. Journal Of Neuromuscular Diseases. 2026; 13(1)DOI:10.3233/JND-230091. PMID:38728200. IF:3.400(Q2/3D).

Allen, JA, Querol, L, Suresh, N, Remmerie, A, Mole, T, McCoy, K, Butler, L, van Hoorick, B, Kuwabara, S, van Doorn, PA, Lewis, RA. Efgartigimod as a treatment for people with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): a plain language summary of publication of the ADHERE trial. Therapeutic Advances in Neurological Disorders. 2026; 19DOI:10.1177/17562864251405202. PMID:41583073. IF:4.100(Q1/2D).